Format

Send to

Choose Destination
Cardiovasc Res. 2017 Sep 1;113(11):1418-1419. doi: 10.1093/cvr/cvx137.

Melatonin as a cardioprotective therapy following ST-segment elevation myocardial infarction: is it really promising? Reply.

Author information

1
The Hatter Cardiovascular Institute, University College London, London, UK; The National Institute of Health Research University College London Hospitals Biomedical Research Centre, London, UK; Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore; and National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore; Department of Cardiology, Vall d'Hebron University Hospital and Research Institute. Universitat Autònoma, Barcelona, Spain; Department of Cardiology, Aarhus University Hospital Skejby, DK-8200, Aarhus N, Denmark; The Hatter Cardiovascular Institute, University College London, London, UK; Department of Physiology and Cell Biology, College of Medicine, University of South Alabama, Mobile, AL, USA; Experimental Renal and Cardiovascular Research, Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Duke University, Durham, NC, USA; Department of Medicine, Hatter Institute for Cardiovascular Research in Africa and South African Medical Research Council Inter-University Cape Heart Group, Faculty of Health Sciences, University of Cape Town, Chris Barnard Building, Anzio Road, Observatory, 7925, Cape Town, Western Cape, South Africa; Tamman Cardiovascular Research Institute, Sheba Medical Center, Tel Hashomer, Israel; Neufeld Cardiac Research Institute, Tel-Aviv University, Sheba Medical Center, Tel Hashomer, Israel; Sheba Center for Regenerative Medicine, Stem Cell, and Tissue Engineering, Tel Hashomer, Israel; Institute of Cardiology and Center of Excellence on Aging, 'G. d'Annunzio' University - Chieti, Italy; Texas Heart Institute and University of Texas Medical School in Houston, Department of Internal Medicine, Houston, TX, USA; Explorations Fonctionnelles Cardiovasculaires, Hôpital Louis Pradel, Lyon, France UMR 1060 (CarMeN), Université Claude Bernard, Lyon, France; Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy; University of Angers, University Hospital of Angers, Department of Cardiology, Angers, France; Institute of Physiology, Justus-Liebig University of Giessen, Giessen, Germany; Cardiology and UMC Utrecht Regenerative Medicine Center, University Medical Center Utrecht, the Netherlands; University Medical Center Utrecht, Division Heart and Lungs, and Hubrecht Institute, Utrecht, the Netherlands; Division of Cardiothoracic Surgery, Department of Surgery, Emory University, Atlanta, GA, USA; The Hatter Cardiovascular Institute, University College London, London, UK; and The National Institute of Health Research University College London Hospitals Biomedical Research Centre, London, UK; Cardiovascular Research Group, Department of Medical Biology, UiT, The Arctic University of Norway, Tromsø, Norway; Institute for Pathophysiology, West-German Heart and Vascular Center, University Hospital Essen, Essen, Germany; Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary; and Pharmahungary Group, Szeged, Hungary.
PMID:
28859295
DOI:
10.1093/cvr/cvx137
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center